Stay updated with breaking news from Todd Fox. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) Safety in these pediatric populations was...
Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions - News - PharmaTimes
As the summer music season begins, HI-FI founder and MOKB Presents president Josh Baker reflects on two years that definitely did not rock.
Southeastern High School held its 2022 commencement ceremony on May 22 for 28 graduates.
Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis ...